Journal article 64 views 60 downloads
Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales
Steven Kerr,
Stuart Bedston,
Declan T Bradley,
Mark Joy,
Emily Lowthian,
Rachel M Mulholland,
Ashley Akbari 
,
F D Richard Hobbs,
Srinivasa Vittal Katikireddi ,
Simon de Lusignan ,
Igor Rudan,
Fatemeh Torabi ,
Ruby S M Tsang,
Ronan Lyons ,
Chris Robertson,
Aziz Sheikh
,
F D Richard Hobbs,
Srinivasa Vittal Katikireddi ,
Simon de Lusignan ,
Igor Rudan,
Fatemeh Torabi ,
Ruby S M Tsang,
Ronan Lyons ,
Chris Robertson,
Aziz Sheikh
International Journal of Epidemiology
Swansea University Authors:
Stuart Bedston, Emily Lowthian, Ashley Akbari , Fatemeh Torabi , Ronan Lyons
-
PDF | Version of Record
Copyright: The Author(s) 2022. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
Download (779.52KB)
DOI (Published version): 10.1093/ije/dyac199
Abstract
BackgroundSeveral SARS-CoV-2 vaccines have been shown to provide protection against COVID-19 hospitalization and death. However, some evidence suggests that notable waning in effectiveness against these outcomes occurs within months of vaccination. We undertook a pooled analysis across the four nati...
| Published in: | International Journal of Epidemiology |
|---|---|
| ISSN: | 0300-5771 1464-3685 |
| Published: |
Oxford University Press (OUP)
2022
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa61634 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
BackgroundSeveral SARS-CoV-2 vaccines have been shown to provide protection against COVID-19 hospitalization and death. However, some evidence suggests that notable waning in effectiveness against these outcomes occurs within months of vaccination. We undertook a pooled analysis across the four nations of the UK to investigate waning in vaccine effectiveness (VE) and relative vaccine effectiveness (rVE) against severe COVID-19 outcomes.MethodsWe carried out a target trial design for first/second doses of ChAdOx1(Oxford–AstraZeneca) and BNT162b2 (Pfizer–BioNTech) with a composite outcome of COVID-19 hospitalization or death over the period 8 December 2020 to 30 June 2021. Exposure groups were matched by age, local authority area and propensity for vaccination. We pooled event counts across the four UK nations.ResultsFor Doses 1 and 2 of ChAdOx1 and Dose 1 of BNT162b2, VE/rVE reached zero by approximately Days 60–80 and then went negative. By Day 70, VE/rVE was –25% (95% CI: –80 to 14) and 10% (95% CI: –32 to 39) for Doses 1 and 2 of ChAdOx1, respectively, and 42% (95% CI: 9 to 64) and 53% (95% CI: 26 to 70) for Doses 1 and 2 of BNT162b2, respectively. rVE for Dose 2 of BNT162b2 remained above zero throughout and reached 46% (95% CI: 13 to 67) after 98 days of follow-up.ConclusionsWe found strong evidence of waning in VE/rVE for Doses 1 and 2 of ChAdOx1, as well as Dose 1 of BNT162b2. This evidence may be used to inform policies on timings of additional doses of vaccine. |
|---|---|
| Item Description: |
Data availability:All code, metadata and documentation for this project is publiclyavailable at https://github.com/EAVE-II/Covid-vaccine-waningpooled. Most of the data that were used in this study are highly sensitive and will not be made available publicly. |
| Keywords: |
COVID-19, vaccine effectiveness, vaccine waning |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
This research is part of the Data and Connectivity National Core
Study, led by Health Data Research UK in partnership with the
Office for National Statistics and funded by UK Research and
Innovation (grant ref MC_PC_20058). The Honest Broker Service
(HBS) is funded by the Business Services Organisation (BSO) and
the Department of Health for Northern Ireland. This work was supported by the Con-COV team funded by the Medical Research
Council (grant number: MR/V028367/1). This work was supported
by Health Data Research UK, which receives its funding from HDR
UK Ltd (HDR-9006) funded by the UK Medical Research Council,
Engineering and Physical Sciences Research Council, Economic and
Social Research Council, Department of Health and Social Care
(England), Chief Scientist Office of the Scottish Government Health
and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency
(Northern Ireland), British Heart Foundation and the Wellcome
Trust. This work was supported by the ADR Wales programme of
work. The ADR Wales programme of work is aligned to the priority
themes as identified in the Welsh Government’s national strategy:
Prosperity for All. ADR Wales brings together data science experts
at Swansea University Medical School, staff from the Wales Institute
of Social and Economic Research, Data and Methods (WISERD) at
Cardiff University and specialist teams within the Welsh
Government to develop new evidence that supports Prosperity for
All by using the SAIL Databank at Swansea University, to link and
analyse anonymized data. ADR Wales is part of the Economic and
Social Research Council (part of UK Research and Innovation)
funded ADR UK (grant ES/S007393/1). This work was supported
by the Wales COVID-19 Evidence Centre, funded by Health and
Care Research Wales. |